Aurora Cannabis Inc. (NYSE: ACB) announced Monday that founder and former CEO Terry Booth has disclosed the sale of around 12.16 million shares of the company.The sale of Aurora's shares is linked with Booth's resignation from the position of CEO last month, the cannabis company said."The board and management remain focused on the plan we laid out in February and we are progressing as planned toward appropriate capital allocation, balance sheet strength, and profitability. We look forward to updating the markets on our next quarterly earnings call," Executive Chairman and Interim CEO Michael Singer said in a statement.Aurora's shares were trading 5.42% lower at 73 cents per share during Monday's pre-market session.Related Links:Why Restructuring Efforts Don't Necessarily Signal The End Of A Cannabis Company's DownturnAurora Cannabis Analyst Sees Power In Restructuring, Still Projects Stock VolatilityPhoto courtesy of Aurora. See more from Benzinga * Tilray Shares Fall After Q4 Print, Analyst Questions...
The outbreak of COVID-19 caused by the new coronavirus SARS-CoV-2 is roiling the global economy. The pandemic has caused more than 6,500 deaths, according to Johns Hopkins University. About 35 vaccine candidates with different modes of action are in development for COVID-19, according to the World Health Organization. The following are coronavirus vaccine candidates in development along with the sponsor, vaccine type and stage of development:Inovio Pharmaceuticals Inc (NASDAQ: INO) * Type of Vaccine: DNA plasmid vaccine * Stage of Development: PreclinicalInovio has received funding from multiple agencies for developing INO-4800 and an intradermal delivery device for the vaccine. An accelerated timeline provided by the company points toward INO-4800 entering clinics by April. The company hopes to make available 1 million doses of the vaccine by end of 2020.Applied DNA Sciences Inc (NASDAQ: APDN) & Takis Biotech * Type of Vaccine: Linear DNA vaccine * Stage of Development: PreclinicalAfter revealing Feb....
Ned Davis Research Tim Hayes and Matt Maley, equity strategist at Miller Tabak + Co, join The First Trade to discuss the market volatility during the coronavirus outbreak and how investors should react throughout the current market pressure and uncertainty....
Confirmed cases of coronavirus disease in the US have expanded dramatically, from only 100 just two weeks ago to more than 3,300 now. As the disease spreads, the Federal government has declared a national emergency and released $50 billion in aid for States and territories to fight the viral outbreak. At the same time, the Federal Reserve cut its key interest rate back to near-zero, and announced that it will initiate a $700 billion program of quantitative easing.The governmental moves, welcomed by the business community, have at best only partially stemmed the feeling of panic in the general public. Grocery stores are reporting long times – sometimes around the corner – and depleted stocks of household cleaners, hand sanitizers, and food staples. And we’ve all heard the stories (and seen the jokes) about toilet paper hoarding.The consensus outlook is that COVID-19 will get worse before it gets better. Quarantines, social distancing,...